Anglo-Swedish drugmaker AstraZeneca could spin off its Chinese division and list it in Hong Kong to minimise China-related risks, the Financial Times reported on Monday.
The company started discussions several months ago, the business daily said citing people familiar with the talks.
AstraZeneca declined to comment.
According to the FT, the drugmaker was seeking to diminish the risk of any potential Chinese crackdown on foreign companies.
